Jianguang Yang

Jianguang Yang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in Cancer Medicine
Verified
Journal Article
Open access
YLYangbo Lv
Yangbo Lv
SLShuiquan Lin
Shuiquan Lin
MLMingsheng Liu
Mingsheng Liu
LWLihui Wang
Lihui Wang
XWXiaoyu Wang
Xiaoyu Wang
JYJianguang Yang
Jianguang Yang
Background: Although diabetes mellitus (DM) is regarded as a risk factor of colorectal cancer (CRC), the impacts of pre‐existing DM on CRC without drug intervention remain unknown. The purpose of this study was to investigate and analyze the effects of diabetes mellitus (DM) on colorectal cancer (CRC). And, to further explore the influencing factors and the mechanisms of DM affects CRC progression.Methods: In this study, we investigated the effects of DM on CRC progression in a streptozotocin‐induced DM mice model. Furthermore, we evaluated the change of T cells levels using flow cytometry and indirect immunofluorescence. We assessed the alternation of gut microbiome and the transcriptional response using 16s rRNA sequencing and RNA‐seq.Results: Results showed that the mice survival time was significantly decreased in CRC complicated with DM group (DM‐CRC), compared with only tumor bearing mice (CRC group). Furthermore, we found that DM could affect the immune response by changing the infiltration of CD4+ T cells, CD8+ T cells and mucosal‐associated invariant T cell (MAIT) in the CRC progression. In addition, DM could induce gut microbiome dysbiosis and change the transcriptional response in CRC complicated with DM.Conclusion: For the first time, the effects of DM on CRC were systematically characterized in a mice model. Our findings highlight the effects of pre‐existing DM on CRC, and these findings should facilitate further studies in exploring and developing potentially targeted therapy for CRC in diabetic patients. Our results suggest that the effects induced by DM should be considered in the treatment for CRC complicated with DM patients.

20 May 2026 in Materials Today Bio
Verified
Journal Article
Open access
JJJiahui Jiang
Jiahui Jiang
YLYangbo Lv
Yangbo Lv
MMMengyuan Ma
Mengyuan Ma
HXHanyue Xu
Hanyue Xu
MSMingxin Sun
Mingxin Sun
JYJianguang Yang
Jianguang Yang
Hydrogels are widely recognized as promising carriers for antitumor drug delivery owing to their tunable physicochemical properties. However, elevated interstitial fluid pressure and a dense extracellular matrix within tumors often restrict efficient drug penetration. Herein, we developed a nanomotor-based injectable hydrogel (CPPZ@R837) that integrates Janus-type polydopamine nanobowls (PDA NBs) functionalized with platinum nanoparticles (Pt NPs) as catalytic propellants and zinc phthalocyanine (ZnPc) as a photosensitizer to construct PPZ nanomotors (NMs). These PPZ NMs, together with the immunoadjuvant imiquimod (R837), were embedded into a chitosan (CTS)-based thermosensitive hydrogel through Michael addition and Schiff base reactions. Upon laser irradiation, the hydrogel underwent a sol-gel phase transition, enabling the controlled release of PPZ NMs and R837. The Pt NPs catalyzed the decomposition of tumor-overexpressed hydrogen peroxide (H2O2) to generate oxygen (O2), which not only provided propulsion for the NMs but also alleviated tumor hypoxia, thereby enhancing the efficacy of photodynamic therapy (PDT). This multifunctional system markedly improved intratumoral drug penetration and exhibited potent antitumor performance, achieving significant tumor growth inhibition (83.7%) and effective suppression of metastasis. Collectively, these findings highlight the great potential of this nanomotor-based hydrogel as an advanced platform for synergistic cancer therapy.